[Auditory assessment in a protocol of concurrent carboplatin and irradiation use in fractionated therapy].
Possible ototoxicity related with a hyperfractionated concurrent chemo-radiation schedule was studied in 36 patients with head and neck cancer. The schedule consisted of two daily fractions, each consisting of 5 mg/m2 of carboplatin plus 115 cGy. Therapy was given 5 days a week for 7 weeks up to a total dose of 700 mg carboplatin and 8050 cGy. Tonal audiograms and superliminal tests were carried out before treatment, at conclusion, six months post-treatment, and every year thereafter. After a mean follow-up of 18 months (maximum 30 months), no treatment-related sensorineural hearing loss was observed. However, recruitment disappeared in post-treatment superliminal tests in 37% of patients who presented sensorineural deafness with recruitment, although it reappeared in audiograms recorded six months later. We attributed this to transient demyelinization. After treatment, a previous tympanosclerosis reactivated in 1 case and effusive otitis media occurred in 8 patients. Previous effusive otitis media disappeared in 1 patient (nasopharyngeal tumor).
De Serdio
J L
JL
Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife.
Villar
A
A
Halawa
B F
BF
González-Castro
I
I
Alvarez
I E
IE
Artazkoz
J J
JJ
López-Aguado
D
D
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone / Q000379:methods*; D016190:Carboplatin / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy*; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D016190:Carboplatin
Valoración auditiva en un protocolo con aplicación concomitante de carboplatino e irradiación dentro de cada fracción terapéutica.